Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Pneumovirus" patented technology

A genus of the family PARAMYXOVIRIDAE (subfamily PNEUMOVIRINAE) where the human and bovine virions have neither hemagglutinin nor neuraminidase activity. RESPIRATORY SYNCYTIAL VIRUS, HUMAN is the type species.

Self-assembling protein nanostructures displaying paramyxovirus and / or pneumovirus F proteins and uses thereof

Disclosed herein are nanostructures and uses thereof, comprising a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1, and I53_dn5A.2, or variants thereof, and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides that are I53_dn5B or a variant thereof, wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form the nanostructure; and the nanostructure displays multiple copies of F protein or antigenic fragment thereof of one or more paramyxoviruses and / or pneumoviruses, respectively.
Owner:UNIV OF WASHINGTON

Use of BCG immunogenic formulation expressing a respiratory syncitial virus protein against hMPV

ActiveUS12667611B2BCG immunizationVirus Protein
The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 10-10° bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human Orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human Metapneumovirus (hMPV) infections.
Owner:PONTIFISIA UNIVERSIDAD KATOLIKA DE CHILE

Self-assembling nanostructured vaccine

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.
Owner:UNIV OF WASHINGTON

Self-assembling protein nanostructures displaying paramyxovirus and / or pneumovirus f proteins, and their use

PendingJP2025172875AFungiSsRNA viruses negative-senseAntigenPneumovirus
To provide subunit vaccines with nanostructure-based vaccines.SOLUTION: Provided herein are nanostructures and their use, where the nanostructures include: a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1 and I53_dn5A.2, or variants thereof; and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides being I53_dn5B or a variant thereof; where the first assemblies non-covalently interact with the second assemblies to form a nanostructure; and where the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof.SELECTED DRAWING: None
Owner:UNIV OF WASHINGTON